Loading…
National Computer Forensics Institute Reauthorization Act of 2022
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
83pct
118d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
National Computer Forensics Institute Reauthorization Act of 2022 This bill reauthorizes through FY2032 the National Computer Forensics Institute within the U.S. Secret Service. The bill expands the mission of the institute to include educating, training, and equipping law enforcement officers and others on preventing (in addition to investigating) cybersecurity incidents, electronic crimes, and related cybersecurity threats. The bill requires the institute to develop and share information related to investigating cybersecurity incidents, electronic crimes, and related cybersecurity threats. The bill also requires the institute to report annually on its activities.
Yes
410
No
16
Present
0
Not Voting
4
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · fourth_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $80,000 · Firm income: Not reported
Received in the Senate and Read twice and referred to the Committee on the Judiciary.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 410 - 16 (Roll no. 305). (text: 06/21/2022 CR H5691-5692)
HousePassed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 410 - 16 (Roll no. 305).
HouseConsidered as unfinished business. (consideration: CR H6286)
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
DEBATE - The House proceeded with forty minutes of debate on H.R. 7174.
Considered under suspension of the rules. (consideration: CR H5691-5693)
Mr. Swalwell moved to suspend the rules and pass the bill, as amended.
Bills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| house |
| On Motion to Suspend the Rules and Pass, as Amended |
Passed |
| July 13, 2022 |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program
Client expense: $320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Placed on the Union Calendar, Calendar No. 287.
Committee on the Judiciary discharged.
Committee on the Judiciary discharged.
Reported (Amended) by the Committee on Homeland Security. H. Rept. 117-376, Part I.
Congress.gov source codes: 5000, H12200
Subcommittee on Cybersecurity, Infrastructure Protection, and Innovation Discharged.
Subcommittee on Intelligence and Counterterrorism Discharged.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Cybersecurity, Infrastructure Protection, and Innovation.
Referred to the Subcommittee on Intelligence and Counterterrorism.
Referred to the Committee on Homeland Security, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Markup by |
| May 19, 2022 |
| Judiciary Committee | House | Referred to | March 18, 2022 |
| Homeland Security Committee | House | Referred to | March 18, 2022 |
| March 18, 2022 |
| Republican |
| TN |
| Chris Pappas | Democratic | NH |
| Ed Case | Democratic | HI |
| Eric Swalwell | Democratic | CA |
| Gary J. Palmer | Republican | AL |
| James R. Langevin | Democratic | RI |
| Jerry L. Carl | Republican | AL |
| Mike Rogers | Republican | AL |
| Mo Brooks | Republican | AL |
| Ritchie Torres | Democratic | NY |
| Robert B. Aderholt | Republican | AL |
| Seth Moulton | Democratic | MA |
| Terri A. Sewell | Democratic | AL |
| Tom Malinowski | Democratic | NJ |
| Val Butler Demings | Democratic | FL |
| Yvette D. Clarke | Democratic | NY |